Your doctor hands you a lab printout with a number next to "PSA" and moves on to the next topic before you've finished reading it. Ask what it means and you'll usually get a hedge — "it's a bit elevated, but that's not necessarily concerning" — which tells you almost nothing about whether you should worry. The PSA test has a genuinely confusing reputation, and most of that confusion comes from doctors trying to avoid alarming patients rather than explaining what the number actually measures.
PSA measures a protein, not cancer
Prostate-specific antigen is a protein produced by prostate tissue — all prostate tissue, healthy and cancerous alike. A PSA test doesn't detect cancer directly; it detects a level of protein in your blood that tends to run higher when something is going on in the prostate, which could be cancer, could be an enlarged prostate (benign prostatic hyperplasia, extremely common after 50), could be a recent infection, or could just be recent ejaculation or a bike ride, both of which can bump the number for 24–48 hours. This is why a single elevated PSA reading means almost nothing on its own, and why a doctor ordering an immediate biopsy off one number without a retest is doing you a disservice.
The generally accepted reference range is under 4.0 ng/mL, but that threshold was set decades ago and doesn't scale well with age — a PSA of 3.5 in a 45-year-old carries more weight than the same number in a 70-year-old, whose prostate has simply grown larger over the decades and produces more baseline protein as a result. Age-adjusted reference ranges exist for exactly this reason: under 2.5 for men in their 40s, under 3.5 for men in their 50s, under 4.5 for men in their 60s, under 6.5 for men 70 and older. Most primary care doctors still quote the flat 4.0 cutoff regardless of your age, which is part of why the test confuses more than it clarifies.
The trend matters more than any single number
A PSA of 2.8 that's been stable for five years is a very different situation than a PSA of 2.8 that jumped from 1.2 last year. That rate of change — called PSA velocity — is one of the strongest predictors urologists actually use, and it's also the piece most patients never see, because it requires comparing this year's result against last year's, which your doctor may not pull up unless you specifically ask. Request your last three to five years of PSA results at your next visit and look at the trajectory yourself. A rise of more than 0.75 ng/mL in a single year is generally considered worth a closer look, even if the absolute number is still technically "normal."
This is the single most unqualified recommendation in this entire piece: get a baseline PSA test at 45 if you're Black or have a first-degree relative with prostate cancer, and by 50 for everyone else, then repeat it every one to two years regardless of how normal the first number looks. Skipping the baseline is the mistake that makes every future number harder to interpret, because there's nothing to compare it against.
Free PSA and the ratio nobody mentions
PSA circulates in your blood in two forms — bound to other proteins, or "free" and unbound. When a total PSA comes back in the gray zone, typically 4 to 10 ng/mL, a follow-up test measuring the ratio of free to total PSA adds real diagnostic value that the total number alone can't provide. A lower percentage of free PSA (generally under 10%) correlates with a higher likelihood of cancer being present, while a higher free percentage (above 25%) leans toward benign enlargement. It's not a diagnosis either way — but it's the test that keeps a lot of men out of an unnecessary biopsy, and plenty of doctors don't automatically order it unless the patient asks.
Here's the part that surprises most men: even with all of this nuance, most elevated PSA readings turn out to be benign. Somewhere between two-thirds and three-quarters of men who get a biopsy after an elevated PSA do not have prostate cancer. The test is a screening tool, deliberately built to flag more cases than turn out to be real, because missing an actual cancer is the worse outcome. That tradeoff is reasonable from a population health standpoint — it's just rarely explained to the individual guy sitting in the exam room, wondering if the number he was just handed is a death sentence or a rounding error.
What actually raises PSA that has nothing to do with cancer
A handful of ordinary things push PSA up temporarily, and ruling them out before you spiral over a number is worth the two-minute conversation with your doctor. A urinary tract infection or prostatitis can spike PSA well above baseline — sometimes into double digits — and resolve completely once the infection clears, at which point a repeat test shows the real number. Ejaculation within 48 hours of a blood draw can raise PSA by a small but measurable amount; urologists routinely tell patients to abstain for two days before testing for exactly this reason, though plenty of GPs never mention it when ordering routine bloodwork. A digital rectal exam performed immediately before the blood draw does the same thing, on a smaller scale, and vigorous cycling for the same reason — direct prostate pressure.
None of these caveats mean you should dismiss an elevated number as "probably nothing." They mean that if your PSA comes back high and you had a UTI, rode 40 miles the day before, or had sex that morning, the right move is a retest under clean conditions before jumping to a biopsy — not ignoring the result altogether.
When to push for a urologist referral
Ask for a referral to a urologist — don't wait for your primary care doctor to suggest it — if your PSA is above the age-adjusted range on a confirmed retest, if your PSA velocity exceeds 0.75 ng/mL per year, or if a digital rectal exam turns up anything abnormal regardless of what the PSA number says. A urologist has access to additional tools your GP typically doesn't order first-line: the 4Kscore or PHI (Prostate Health Index) blood tests, both of which refine risk assessment well beyond total PSA alone, and MRI-guided biopsy, which has largely replaced the older random-sampling biopsy technique and catches clinically significant cancer with far fewer false negatives.
Prostate cancer, caught early, has a five-year survival rate above 99% according to American Cancer Society data — among the highest of any cancer type. That statistic exists because of screening, imperfect as the PSA test is. The men who fare worst aren't the ones who got an elevated number and had it investigated properly. They're the ones who never got a baseline test at all, and found out a decade later when symptoms had already progressed past the point where "early" applied.